Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 20/20 | 0.64 |
| ▸ | NSD2 | O96028 | 2/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.53 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20755638 | 0.98 | EHMT2 (0.66) | EHMT2NSD2 | |
| SCHEMBL19260588 | 0.97 | EHMT2 (0.67) | EHMT2NSD2 | |
| SCHEMBL20720587 | 0.96 | EHMT2 (0.65) | EHMT2NSD2 | |
| SCHEMBL19260811 | 0.95 | EHMT2 (0.66) | EHMT2NSD2 | |
| Formic Acid SCHEMBL19260701 | 0.93 | EHMT2 (0.61) | EHMT2NSD2DNMT1DNMT3BDNMT3A | |
| SCHEMBL20755125 | 0.91 | EHMT2 (0.56) | EHMT2NSD2DNMT1DNMT3BDNMT3A | |
| SCHEMBL20755538 | 0.91 | EHMT2 (0.65) | EHMT2NSD2DNMT1DNMT3BDNMT3A | |
| Formic Acid SCHEMBL19260644 | 0.90 | EHMT2 (0.60) | EHMT2NSD2DNMT1DNMT3BDNMT3A | |
| SCHEMBL20755315 | 0.90 | EHMT2 (0.55) | EHMT2NSD2DNMT1DNMT3BDNMT3A | |
| SCHEMBL20755622 | 0.90 | EHMT2 (0.76) | EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885NSD2 141/4885DNMT1 24/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885NSD2 141/4885DNMT1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.